Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Immunome Selects Arrayjet's ArrayPlex Platform for Use in Its Discovery of Targeted Cancer Therapies

Author: Benzinga Newsdesk | March 18, 2024 05:51am

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools. The proprietary multi-layer microarray platform is also available to Arrayjet's screening customers through its CRO/CMO services or by the customer purchasing an instrument and performing screening in-house.

Posted In: IMNM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist